Loading...
NPI 1720170053 · Dothan, AL · Hematology & Oncology Physician
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Michael Mcallister is a hematology & oncology physician provider located in Dothan, Alabama. This profile covers 47 Medicare and 2 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Individual |
| Organization | Michael Mcallister |
| Address | 287 Healthwest Dr |
| City | Dothan |
| State | AL |
| ZIP | 36303 |
| Taxonomy | Hematology & Oncology Physician |
| NPI Enumerated | September 28, 2006 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $1.8M |
| Medicaid | $0 |
This provider is effectively a Medicare-only biller at scale: lifetime Medicare revenue is $1.8M while Medicaid revenue is $0, indicating the provider’s entire recorded public-payer footprint in the dataset is Medicare. That concentration implies payer risk and competitive analysis should focus on Medicare fee schedules, beneficiary referral pathways, and outpatient oncology reimbursement dynamics in DOTHAN, AL.
Revenue is highly concentrated in a very small set of drugs and infusions: the precomputed top 3 Medicare codes by revenue account for 74.5% of this provider's total Medicare revenue, led by J9271 at $963.2K (53.9% of Medicare revenue), followed by J0897 at $250.6K (14.0%) and J1449 at $116.7K (6.5%). This concentration shows the practice’s financial performance is materially driven by a handful of high-cost oncology and supportive-care injectables rather than broad E/M or diagnostic revenue streams.
The code mix and volumes indicate a focused oncology infusion practice that administers high-cost systemic therapy and supportive agents: J9271 (pembrolizumab) shows 22.4K claims and $963.2K revenue, J0897 (denosumab) shows 13.9K claims and $250.6K revenue, and J1449 (eflapegrastim) shows 4.5K claims and $116.7K revenue. In combination with chemotherapy administration codes (96413, 96417, 96415, 96401) and infusion visit codes (96367, 96365), the profile is consistent with regular in-office infusion sessions plus ancillary supportive-care injections.
Competitive standing is mixed: for the top revenue driver J9271 the provider ranks #295 of 1841 nationally (84th percentile) which the data labels as "typical, unremarkable volume"—meaning solid but not dominant market share for pembrolizumab. By contrast, the provider is an above-typical outlier on several administration and supportive-care codes — for example J1627 ranks #4 of 119 (97th percentile; "notably above typical national volume") and 96413 ranks #203 of 7514 (97th percentile; "notably above typical national volume"), suggesting the practice is comparatively active in procedural administration relative to peers.
Visit-level E/M activity is present but secondary to infusion revenue: 99215 accounts for 333 claims and $43.6K (2.4% of Medicare revenue) and 99214 accounts for 446 claims and $39.2K (2.2%). The presence of higher-level E/M codes alongside intensive infusion billing indicates the provider manages complex oncology patients with significant clinical decision-making during office encounters, supporting a practice model of combined consultation and infusion services.
Several codes show extreme throughput of low–unit-value supplies or antiemetics, which points to high patient volumes per treatment episode: for example J0185 appears with 31.1K claims and $31.1K revenue (1.7% of Medicare revenue) but only $1 avg paid/claim, while J1627 has 20.5K claims and $102.5K revenue (5.7%). These patterns are consistent with frequent, small-unit supportive medications being administered repeatedly as part of standard oncology regimens.
Operationally, procedure-level add-ons and infusion-continuation codes are used at above-typical rates, supporting a throughput-intensive infusion operation: 96417 has 241 claims and $10.8K (0.6% of Medicare revenue) and 96415 has 211 claims and $4K (0.2% of Medicare revenue), both ranked well above typical national volume (96th and 89th percentiles respectively). Together with high rankings on codes like 96367 (#66 of 4032, 98th percentile), this suggests extended or multi-drug infusion sessions are a routine part of the practice’s workflow.
The provider has long tenure in the NPI registry (enumerated 2006-09-28, ~20 years ago), which supports interpreting these billing patterns as established practice behavior rather than a short-term anomaly. Given the combination of long enumeration, Medicare-only revenue, and a drug-heavy revenue mix, analysts should treat this entity as an established, outpatient oncology infusion provider whose financial profile is tightly tied to a few high-revenue oncology drugs and frequent supportive-care administrations.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
47 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | 22,400 | $40 | $963.2K |
| J0897 | Injection, denosumab, 1 mg | 13,920 | $20 | $250.6K |
| J1449 | Injection, eflapegrastim-xnst, 0.1 mg | 4,490 | $30 | $116.7K |
| J1627 | Injection, granisetron, extended-release, 0.1 mg | 20,500 | $10 | $102.5K |
| 96413 | Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These… | 770 | $90 | $68.3K |
| 99215 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a high level of medical decision making, and/or the… | 330 | $130 | $43.6K |
| J9305 | Injection, pemetrexed, not otherwise specified, 10 mg | 3,910 | $10 | $43K |
| 99214 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the… | 450 | $90 | $39.2K |
| J0185 | Injection, aprepitant, 1 mg | 31,070 | $1 | $31.1K |
| 96367 | The provider administers an additional intravenous infusion or infusions, after an initial infusion, of a different medication or substance for a period up to one hour to prevent, treat, or diagnose… | 1,060 | $20 | $21.1K |
Showing 1–10 of 47
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 47 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
47 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| J9271 | 9 | 30 | 19,900 | $40 | $827.2K |
| J1449 | 2 | 10 | 4,550 | $30 | $115.7K |
| J0897 | 15 | 200 | 3,120 | $20 | $97.7K |
| J1627 | 1 | 10 | 14,400 | $1 | $69.9K |
| J1437 | 41 | 40 | 3,000 | $20 | $59.1K |
| J9305 | 1 | 10 | 3,910 | $10 | $43.7K |
| 96413 | 5 | 150 | 150 | $90 | $20.2K |
| 99214 | 974 | 7,330 | 120 | $80 | $16.8K |
| 80053 | 506 | 670 | 140 | $10 | $13.1K |
| J0185 | 1 | 20 | 5,980 | $1 | $12.9K |
Showing 1–10 of 47
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
2 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 36415 | In this procedure, the provider inserts a needle into a vein to collect a blood sample. | 20 | $0 | $0 |
| 85025 | A complete blood count (better known as a CBC) is a blood test request by a doctor that provides detailed information about various types of cells in a patient's blood. Usually a pathologist or a… | 60 | $0 | $0 |
How this provider's Medicaid billing volume and revenue compare to other Alabama providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Alabama median
2 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| 85025 | A complete blood count (better known as a CBC) is a blood test request by a doctor that provides detailed information about various types of cells in a patient's blood. Usually a pathologist or a… | 323 | 370 | 1,540 | $10 | $65K |
| 36415 | In this procedure, the provider inserts a needle into a vein to collect a blood sample. | 470 | 520 | 300 | $1 | $2.7K |
Other providers in the same ZIP code as Michael Mcallister, ranked by combined Medicare and Medicaid revenue.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.